IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd.

Delivers Market-Leading Competitive Intelligence Capabilities with Addition of Industry’s Most Comprehensive Database for Licensing and M&A Insights

IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd.

<0> IMS HealthGary Gatyas, +1-610-244-2600 </0>

IMS Health today announced the acquisition of PharmaDeals Ltd., a market-leading provider of online information about business transactions, licensing, and mergers & acquisitions activity within the global pharmaceutical industry. PharmaDeals, the U.K.-based subsidiary of PharmaVentures Ltd., maintains a web-based subscription database containing more than 46,000 records of industry transactions and 16 years of historical data.

PharmaDeals becomes part of IMS’s syndicated analytics and insights that help healthcare clients with their real-time decision making in the areas of market assessment, forecasting, and lifecycle & portfolio management. This addition complements IMS’s sophisticated portfolio of competitive intelligence capabilities, which include company benchmarking, sales force sizing and therapeutic analyses. Clients use this intelligence to analyze the market, the competition and new growth opportunities.

“We are very excited to extend our business analytics and insights to deliver even greater value to clients,” said Anne Delaney, general manager, IMS. “To properly assess the value of partnerships and licensing opportunities, clients need to understand the landscape of transactions in the context of real-world evidence. Now we can bring these perspectives together in a unique and innovative way as the industry continues to transform and healthcare stakeholders look for new partnerships and opportunities for growth.”

Said PharmaVentures Chief Executive Dr. Fintan Walton, “The PharmaDeals database is the recognized gold standard in terms of its coverage, quality and depth. I am confident that integrating these insights with IMS’s robust information and technology assets will open up a new set of possibilities for decision making. The move of PharmaDeals to IMS will enable PharmaVentures to expand its traditional and larger core business of M&A and licensing advisory services.”

PharmaVentures Ltd. () is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. Over recent years, its core advisory business has expanded from licensing and valuation services to the M&A and divestment of R&D and manufacturing businesses for major pharmaceutical companies world-wide. The firm has an established track record in generating outstanding value for its clients and has assisted in over 600 transaction-related assignments, including mandates over the past 20 years.

IMS Health is a leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and software platforms to help clients better understand the performance and dynamics of healthcare systems. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at .

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.